Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 4 1

Status

Unknown 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 91Neoplasm Metastasis 7Prostatic Neoplasms, Castration-Resistant 5Breast Neoplasms 3Neoplasms 2Castration-resistant Prostate Cancer 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Salivary Glands Tumors 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Hyperaldosteronism 1Cushing Syndrome 1Carcinoma, Transitional Cell 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

Abiraterone Acetate 5enzalutamide 4abiraterone 3Prednisone 3apalutamide 2Nivolumab 2Docetaxel 2pembrolizumab 1niraparib 1darolutamide 1cabazitaxel 1Pluvicto 1Omeprazole 1Ipilimumab 1Drug Therapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms, Castration-Resistant × Abiraterone Acetate × Clear all
NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05393791 2024-11-26

ANZadapt

Leiden University Medical Center

Phase 2 Recruiting
168 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05156450 2021-12-14

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

West China Hospital

Phase 2 Unknown
30 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03173859 2020-11-18

AERA

University of Athens

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02254785 2017-12-06

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

British Columbia Cancer Agency

Phase 2 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡